Twist Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Twist Bioscience (TWST).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

10Buy

3Hold

2Sell

Consensus RatingBuy# Analysts15Avg. Consensus PT$109Upside to Avg. PT-26.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$115→$190
Oct 12, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$120→$205
Oct 8, 2026	Jefferies	Matthew Stanton	Initiate	Hold	$150
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$112→$215
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$107→$212
Sep 29, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$160→$190
Sep 18, 2026	BWS Financial	Hamed Khorsand	Maintained	Sell	$45
Sep 17, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$120→$160
Sep 9, 2026	BWS Financial	Hamed Khorsand	Initiate	Sell	$45
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$144
Aug 5, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$85→$115
Aug 4, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$113→$115
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$90→$120
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	Downgrade	Outperform→In-Line	$66→$102
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$60→$107
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$65→$95
Jun 15, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$68→$89
Jun 15, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$90
Jun 11, 2026	Piper Sandler	David Westenberg	Initiate	Overweight	$85
May 5, 2026	Leerink Partners	Puneet Souda	Upgrade	Market Perform→Outperform	$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190

TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $115 to $190.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.

Benzinga Newsdesk

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($540).

Avi Kapoor

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

Jefferies analyst Matthew Stanton initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Hold rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $112 to $215.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $107 to $212.

Benzinga Newsdesk

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

People Also Watch

People Also Watch

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190

PROCanaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205

This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROJefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PROBarclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PROGuggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205

PRO
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212